Development of gene therapy with a cyclic adenosine monophosphate response element decoy oligodeoxynucleotide to prevent vascular intimal hyperplasia

Add time:09/09/2019    Source:sciencedirect.com

ObjectiveIntimal hyperplasia (IH) is the main cause of therapeutic failure after vascular and endovascular surgery. However, there is currently no targeted therapy for the treatment of IH. We recently reported that the inhibition of cyclic adenosine monophosphate response element (CRE) binding protein (CREB) activation is important in vein graft IH. We focused on a decoy oligodeoxynucleotide (ODN) therapeutic strategy for suppressing IH as a clinical application. The objective of this study was to confirm the therapeutic effect of a CRE decoy ODN in an animal model as a novel therapy for preventing intimal hyperplasia as the first step of the preclinical study of our strategy.

We also recommend Trading Suppliers and Manufacturers of 3,N(4)-etheno-3'-deoxyguanosine monophosphate (cas 133073-61-7). Pls Click Website Link as below: cas 133073-61-7 suppliers

Prev:One flask synthesis of 2′,3′-cyclic nucleoside monophosphates from unprotected nucleosides using activated cyclic trimetaphosphate
Next:Data ArticleNon-isothermal decomposition of 4-((4-fluoro-3-phenoxy- benzylidene) amino) benzenesulfonamide under oxygen atmosphere)